Dr. Hui Xiong | Bio Materials | Best Researcher Award

Associate Professor | China Pharmaceutical University | China

Dr. Hui Xiong is an Associate Professor in the Department of Pharmaceutics at China Pharmaceutical University. Her work bridges pharmaceutics, tumor biology, and nanomedicine engineering to create advanced drug delivery systems that improve cancer treatment outcomes. SCI-indexed publications as first or corresponding author, her research contributions have been featured in high-impact journals such as ACS Nano, Nano Letters, Journal of Controlled Release, Small, and Advanced Healthcare Materials. She holds an H-index of 16, four national invention patents, and has secured multiple research grants from the National Natural Science Foundation of China and other prestigious programs. Dr. Xiong’s research emphasizes multifunctional nanocarriers, targeted therapy, tumor microenvironment modulation, and ferroptosis-inducing strategies, particularly for breast cancer. Her translational approach seeks to bridge laboratory innovation with clinical applications, offering new therapeutic paradigms in oncology. Through her leadership and contributions, she has established herself as a rising scholar in nanomedicine-driven pharmaceutics.

Professional Profile

Scopus

Education

Dr. Hui Xiong obtained her Ph.D. in Pharmaceutics from China Pharmaceutical University, one of the leading institutions for pharmaceutical sciences in China. During her doctoral studies, she specialized in advanced drug delivery systems, focusing on the design of multifunctional nanocarriers to overcome therapeutic limitations in cancer treatment. Her doctoral research introduced novel hydroxyapatite-based dual-targeted nanoparticles that enhanced the efficacy of chemotherapeutic drugs, laying the foundation for her later work on multifunctional nanoplatforms. Her training combined pharmaceutics, materials science, and tumor biology, allowing her to integrate multidisciplinary strategies for addressing challenges such as poor bioavailability, tumor heterogeneity, and drug resistance. Following her doctoral training, she expanded her expertise by engaging in postdoctoral projects supported by national and provincial research programs. This educational foundation not only provided her with strong theoretical and technical skills but also shaped her research trajectory toward translational nanomedicine and oncology-focused pharmaceutics.

Experience

Dr. Hui Xiong currently serves as an Associate Professor in the Department of Pharmaceutics at China Pharmaceutical University. She has established an independent research program focusing on cancer-targeted nanomedicine and innovative drug delivery platforms. Over the years, she has published extensively in top-tier journals, including ACS Nano, Nano Letters, and Journal of Controlled Release. She has successfully led multiple projects funded by the National Natural Science Foundation of China, China Postdoctoral Science Foundation, and Jiangsu Provincial Research Grants. Beyond publishing Dr. Xiong has also filed and secured four national invention patents, underscoring her commitment to both academic advancement and practical innovation. She is recognized for her work in creating rationally designed drug carriers that integrate features such as stimuli-responsiveness, tumor microenvironment modulation, and combination therapy strategies. Through her academic and research positions, Dr. Xiong has cultivated expertise that translates pharmaceutics research into clinically applicable cancer therapies.

Research Focus

Dr. Hui Xiong’s research is centered on the rational design and development of advanced nanomedicine platforms for cancer therapy. Her work integrates pharmaceutics, materials science, and tumor biology to address major limitations of traditional chemotherapy, including poor bioavailability, drug resistance, and systemic toxicity. She focuses on designing multifunctional and stimuli-responsive nanocarriers capable of precise targeting, controlled release, and tumor microenvironment remodeling. Key directions of her research include pH-activated antiangiogenic therapies, ferroptosis-inducing nanodrugs, vascular normalization strategies, and immune modulation approaches. Her translational research emphasizes applications in breast cancer and pancreatic cancer, where innovative nanoplatforms have demonstrated improved therapeutic indices and synergistic combination effects. Recent studies include self-assembled nano-activators for ferroptosis-immunotherapy, redox-regulated nanodrugs, and bioengineered nanospores targeting tumor-associated macrophages. Ultimately, her research goal is to transform laboratory discoveries into clinically relevant therapies that enhance the precision, safety, and efficacy of oncology treatments, paving the way for next-generation pharmaceutics innovations.

Awards and Honors

Throughout her academic career, Dr. Hui Xiong has received numerous recognitions for her contributions to pharmaceutics and nanomedicine. She has been awarded prestigious funding programs, including the National Natural Science Foundation of China Youth Program, the China Postdoctoral Science Foundation, the China Postdoctoral Science Foundation Special Grant, and the Jiangsu Provincial Postdoctoral Research Grant. These awards highlight her scientific achievements and the national recognition of her research potential. In addition to grant support, her publications have earned attention in high-impact journals, with one study featured on the front cover of Advanced Healthcare Materials. Her H-index and total journal impact factor exceeding reflect her influence in the scientific community. Holding four national patents further emphasizes her contribution to pharmaceutical innovation. These honors collectively demonstrate her success in both academic research and translational innovation, positioning her as an influential figure in the field of pharmaceutics-driven cancer nanomedicine.

Publication Top Notes

Dr. Hui Xiong’s impressive research experience, publication record, innovative research, and significant funding make her a strong candidate for the Best Researcher Award. With some additional interdisciplinary collaboration, global impact, and translational research, she could further solidify her position as a leading researcher in her field.